ON-III inhibits erbB-2 tyrosine kinase receptor signal pathway and triggers apoptosis through induction of Bim in breast cancer cells

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Cancer Biology & Therapy

• Publication date

  2009-04-15

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.4161/cbt.8.8.7917PMID 19242112
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications

  2008cited by this paper
• Her2 cross talk and therapeutic resistance in breast cancer.

  2008cited by this paper
• Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.

  2008cited by this paper
• Acquired Resistance to Small Molecule ErbB2 Tyrosine Kinase Inhibitors

  2008cited by this paper
• Oncogenic B-RafV600E Inhibits Apoptosis and Promotes ERK-dependent Inactivation of Bad and Bim*

  2008cited by this paper
• Induction of BIM Is Essential for Apoptosis Triggered by EGFR Kinase Inhibitors in Mutant EGFR-Dependent Lung Adenocarcinomas

  2007cited by this paper
• HER-2 and NF-kappaB as the targets for therapy-resistant breast cancer.

  2006cited by this paper
• SUCI02 inhibits the erbB‐2 tyrosine kinase receptor signaling pathway and arrests the cell cycle in G1 phase in breast cancer cells

  2006cited by this paper
• Mechanisms of Disease: understanding resistance to HER2-targeted therapy in human breast cancer

  2006cited by this paper
• Blockade of Vascular Endothelial Growth Factor Receptor Signal Pathway and Antitumor Activity of ON-III (2′,4′-Dihydroxy-6′-methoxy-3′,5′-dimethylchalcone), a Component from Chinese Herbal Medicine

  2005cited by this paper
• Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins.

  2005cited by this paper
• Endogenous anti-HER2 antibodies block HER2 phosphorylation and signaling through extracellular signal-regulated kinase.

  2005cited by this paper
• Herceptin Down-Regulates HER-2/neu and Vascular Endothelial Growth Factor Expression and Enhances Taxol-Induced Cytotoxicity of Human Ewing's Sarcoma Cells In vitro and In vivo

  2005cited by this paper
• Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function.

  2005cited by this paper
• EGF receptor expression, regulation, and function in breast cancer

  2004cited by this paper
• Role of HER2/neu in tumor progression and therapy.

  2004cited by this paper
• Newer therapies in advanced prostate cancer.

  2004cited by this paper
• The ErbB/HER receptor protein-tyrosine kinases and cancer.

  2004cited by this paper
• Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer.

  2004cited by this paper
• Reactive Oxygen Species as Downstream Mediators of Angiogenic Signaling by Vascular Endothelial Growth Factor Receptor-2/KDR*

  2002cited by this paper
• Untangling the ErbB signalling network

  2001cited by this paper
• PUMA induces the rapid apoptosis of colorectal cancer cells.

  2001cited by this paper
• Downregulation of Bim, a Proapoptotic Relative of Bcl-2, Is a Pivotal Step in Cytokine-Initiated Survival Signaling in Murine Hematopoietic Progenitors

  2001cited by this paper
• c-erbB-2 Gene Amplification in Nasopharyngeal Carcinoma

  2000cited by this paper
• ZD1839 ('Iressa') as an anticancer agent.

  2000cited by this paper
• Cell signaling by receptor tyrosine kinases.

  2000cited by this paper
• Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets

  2000cited by this paper
• Overexpression of ErbB2 in cancer and ErbB2-targeting strategies

  2000cited by this paper
• Epidermal growth factor promotes MDA-MB-231 breast cancer cell migration through a phosphatidylinositol 3'-kinase and phospholipase C-dependent mechanism.

  1999cited by this paper
• HER-2/neu oncogene amplification by fluorescence in situ hybridization in epithelial tumors of the ovary.

  1999cited by this paper
• ErbB-1 and ErbB-2 Acquire Distinct Signaling Properties Dependent upon Their Dimerization Partner

  1998cited by this paper
• Bim: a novel member of the Bcl‐2 family that promotes apoptosis

  1998cited by this paper
• Epidermal growth factor and betacellulin mediate signal transduction through co‐expressed ErbB2 and ErbB3 receptors

  1997cited by this paper
• p120 Is a Cytosolic Adapter Protein That Associates with Phosphoinositide 3-Kinase in Response to Epidermal Growth Factor in PC12 and Other Cells (*)

  1996cited by this paper
• Neuregulins in development.

  1996cited by this paper
• Structure-function relationships for the EGF/TGF-alpha family of mitogens.

  1994cited by this paper
• Prognostic significance of HER-2 oncoprotein expression in breast cancer: a 30-year follow-up.

  1992cited by this paper
• HER-2/neu oncoprotein as a prognostic factor in breast cancer.

  1992cited by this paper
• Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.

  1989cited by this paper

• Evaluating skin cancer chemopreventive potential of water extract of Syzygium samarangense leaves through activation of the Nrf2-mediated cellular defense system

  2021cites this paper
• Mechanistic insights into dimethyl cardamonin-mediated pharmacological effects: A double control of the AMPK-HMGB1 signaling axis

  2020cites this paper
• Targeting triple negative breast cancer heterogeneity with chalcones: a molecular insight

  2019cites this paper
• A mechanistic overview of herbal medicine and botanical compounds to target transcriptional factors in Breast cancer.

  2017cites this paper
• Anti-cancer chalcones: Structural and molecular target perspectives.

  2015cites this paper
• Isolation, Characterization, Crystal Structure Elucidation, and Anticancer Study of Dimethyl Cardamonin, Isolated from Syzygium campanulatum Korth

  2014cites this paper
• Molecular targeted approaches to cancer therapy and prevention using chalcones.

  2014cites this paper
• Dual role of 2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone in inhibiting high-mobility group box 1 secretion and blocking its pro-inflammatory activity in hepatic inflammation.

  2014cites this paper
• 2',4'-Dihydroxy-6'-methoxy-3',5'-dimethylchalcone protects the impaired insulin secretion induced by glucotoxicity in pancreatic β-cells.

  2014cites this paper
• 2',4'-Dihydroxy-6'-methoxy-3',5'-dimethylchalcone promoted glucose uptake and imposed a paradoxical effect on adipocyte differentiation in 3T3-L1 cells.

  2014cites this paper
• Hirsutanol A, a novel sesquiterpene compound from fungus Chondrostereum sp., induces apoptosis and inhibits tumor growth through mitochondrial-independent ROS production: Hirsutanol A inhibits tumor growth through ROS production

  2013cites this paper
• The synergistic effects of traditional Chinese herbs and radiotherapy for cancer treatment

  2013cites this paper
• Ceriporia lacerata DMC1106, a new endophytic fungus: Isolation, identification, and optimal medium for 2′,4′-dihydroxy-6′-methoxy-3′,5′-dimethylchalcone production

  2013cites this paper
• In vitro investigation of 2',4'-dihydroxy-6'-methoxy-3',5'-dimethylchalcone for glycemic control.

  2012cites this paper
• Dietary chalcones with chemopreventive and chemotherapeutic potential

  2011cites this paper
• Induction of autophagy by dimethyl cardamonin is associated with proliferative arrest in human colorectal carcinoma HCT116 and LOVO cells

  2011cites this paper
• Glioma Cell Death: Cell–Cell Interactions and Signalling Networks

  2010cites this paper
• The Role of Traditional Chinese Herbal Medicines in Cancer Therapy – from TCM Theory to Mechanistic Insights

  2010cites this paper